Key takeaway
Across 10 studies (1,073 adults with non-dialysis chronic kidney disease), a Mediterranean diet was associated with a modest rise in eGFR (mean difference 2.44 mL/min/1.73 m2, 95% CI 0.16 to 4.72), but heterogeneity was very high (I2 = 90%). The title's claim that it "slows decline" goes beyond a pooled mix of interventional and observational studies.
Study design
Evidence review
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
Whether the Mediterranean diet (MedDiet) protects the kidneys in people with chronic kidney disease (CKD) who are not on dialysis has been inconsistent. The authors tested whether this might be partly because extra virgin olive oil (EVOO) varies in phenolic content, and whether high-phenolic EVOO changes the results.
Who and how
Systematic review and random-effects meta-analysis of interventional and observational studies comparing a MedDiet with control diets in adults with CKD stages 1 to 5, searched across multiple databases. 10 studies with 1,073 participants were included. Outcomes were kidney function (estimated glomerular filtration rate, eGFR) and cardiometabolic measures, with high-phenolic EVOO examined as a possible effect modifier. The review is registered in PROSPERO (CRD420251124826).
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1MedDiet was associated with a modest improvement in eGFR (mean difference 2.44 mL/min/1.73 m2, 95% CI 0.16 to 4.72), with high heterogeneity (I2 = 90%). The benefit appeared more consistent in mild-to-moderate CKD (eGFR 45 or above).
- 2C-reactive protein (CRP), an inflammation marker, fell specifically with interventions using high-phenolic EVOO (mean difference -0.79 mg/L, 95% CI -1.37 to -0.21).
- 3The diet also improved body composition and reduced blood urea nitrogen, without adversely affecting serum potassium or phosphorus.
- 4No significant effects were seen on blood pressure or lipid profiles.
Limits & uncertainty
- 1Heterogeneity was high (I2 = 90%), so studies disagreed and a single pooled number summarizes them poorly.
- 2Pooling interventional and observational studies means results can reflect other healthy habits among those who chose the diet.
- 3Only 10 studies were included, the lower end of the eGFR confidence interval is just 0.16, and the olive-oil finding comes from a subset of studies.
- 4The abstract does not report follow-up length, so conclusions about "slowing decline" over time are not shown. This reading is based on the abstract only.
What to take from it
A Mediterranean-style diet looks compatible with kidney health in early to moderate CKD and did not raise potassium or phosphorus in these studies, but kidney diets are individual, especially in later stages. Ask your kidney team or a renal dietitian before changing what you eat, and before adding supplements or large amounts of any one food.
Reading your own data
Kidney function is tracked by blood tests (eGFR), which a wearable cannot replace. At home, a blood pressure cuff and a weekly weigh-in on the same scale, plus a simple food log to share with a dietitian, are useful. Look at trends across months, not single readings.
How to read this evidence
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
Evidence regarding the renoprotective effect of the Mediterranean diet (MedDiet) in patients with nondialysis chronic kidney disease (CKD) remains inconsistent. This may be partly attributed to variability in the phenolic content of extra virgin olive oil (EVOO), a key bioactive component.
Methods
We conducted a systematic review and meta-analysis to quantify the effect of the MedDiet on renal and cardiometabolic outcomes in adults with nondialysis CKD and to explore the role of high-phenolic EVOO as a potential effect modifier. We searched multiple databases for interventional and observational studies comparing a MedDiet to control diets in adults with CKD stages 1-5. Random-effects meta-analyses were performed.
Results
Ten studies involving 1,073 participants were included. The MedDiet was associated with a modest improvement in estimated glomerular filtration rate (eGFR) (mean difference 2.44 mL/min/1.73 m^(2), 95% CI 0.16 to 4.72), though heterogeneity was high (I^(2) = 90%). This benefit appeared more consistent in mild-to-moderate CKD (eGFR ≥ 45 mL/min/1.73 m^(2)). Notably, a significant reduction in C-reactive protein (CRP) was specifically linked to interventions using high-phenolic EVOO (mean difference -0.79 mg/L, 95% CI -1.37 to -0.21). The diet also improved body composition and reduced blood urea nitrogen, without adversely affecting serum potassium or phosphorus. No significant effects were observed on blood pressure or lipid profiles.
Conclusion
In patients with mild-to-moderate CKD, the MedDiet may slow kidney function decline. The benefits appear to be mediated through complementary pathways: renal protection from the overall dietary pattern and a specific anti-inflammatory effect attributable to high-phenolic EVOO.
Systematic review registration
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251124826, identifier PROSPERO (CRD420251124826).
Sources & attribution
Mediterranean diet with high-phenolic EVOO slows kidney function decline and reduces inflammation in nondialysis CKD: a meta-analysis.
Zhou C, Li Y, Huang M, Bai M, Xing Y.
Frontiers in nutrition · 2026-03-02
DOI: 10.3389/fnut.2026.1792390 ↗PubMed · 41847236 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

